Danish pharma Novo Nordisk posted second-quarter operating profit in line with forecasts but hinted about the possibility of cutting the price of some drugs on the US market next year.
New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.